MDPI and ACS Style
Kanacher, T.; Lindauer, A.; Mezzalana, E.; Michon, I.; Veau, C.; Mantilla, J.D.G.; Nock, V.; Fleury, A.
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. Pharmaceutics 2020, 12, 1191.
https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics12121191
AMA Style
Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Mantilla JDG, Nock V, Fleury A.
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. Pharmaceutics. 2020; 12(12):1191.
https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics12121191
Chicago/Turabian Style
Kanacher, Tobias, Andreas Lindauer, Enrica Mezzalana, Ingrid Michon, Celine Veau, Jose David Gómez Mantilla, Valerie Nock, and Angèle Fleury.
2020. "A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine" Pharmaceutics 12, no. 12: 1191.
https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics12121191